Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04579757 · ClinicalTrials.gov registry record · Phase 1
Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Hutchmed.
- Terminated
- Registry status
- Phase 1
- Development phase
- 87
- Enrollment target
NCT04579757 is a Phase 1 study that was terminated before completion, run by Hutchmed. The registered enrollment target is 87 participants.
The verdict
NCT04579757, a Phase 1 study, was terminated before completion, sponsored by Hutchmed.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 87 participants
- Enrollment target
Study Summary
This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
Interventions
- DRUG Surufatinib and Tislelizumab _ Part 1
- DRUG Surufatinib and Tislelizumab _ Part 2
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 87 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2024-08-27 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04579757
The ClinicalTrials.gov registry entry for NCT04579757 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hutchmed, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surufatinib and Tislelizumab _ Part 1 is the first listed.
NCT04579757 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04579757 about?
NCT04579757 is a clinical study titled "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors". This open-label, phase Ib/II study of surufatinib in combination with tislelizumab will evaluate the safety, tolerability, PK and efficacy in patients with advanced solid tumors. The study consists of 2 parts - dose finding (Part 1) and dose expansion (Part 2).
What is the current status of trial NCT04579757?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2021-03-05. Estimated completion is 2024-08-27.
What interventions are being tested in trial NCT04579757?
The interventions under investigation include: Surufatinib and Tislelizumab _ Part 1 (DRUG), Surufatinib and Tislelizumab _ Part 2 (DRUG).
Who is sponsoring clinical trial NCT04579757?
This trial is sponsored by Hutchmed, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.